What question did this study set out to answer?

To evaluate the safety and efficacy of bb2121 CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

May 20, 2018Journal of Clinical Oncology

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

View Full Paper

Ask AI

Bookmark

Authors

NRNoopur RajeBoston University JBJesús G. BerdejaThe Centers YLYi LinSouth China Agricultural University

Discussion

Member takes

Implication

Randomized trial shows promising efficacy and safety of bb2121 CAR T-cell therapy in relapsed/refractory multiple myeloma, indicating a potential new treatment option.

Key Points

To evaluate the safety and efficacy of bb2121 CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Phase I study (NCT02658929) with dose escalation and expansion phases
Study involved patients with relapsed/refractory multiple myeloma receiving ≥ 3 prior treatments
Patients underwent lymphodepletion before receiving bb2121 infusion.
Overall response rate in eligible patients (n=18) was 94%; 56% achieved complete response (CR)
Cytokine release syndrome (CRS) occurred in 71% of patients, primarily grade 1-2
Median progression-free survival (PFS) has not been reached; rates at 6 months were 81% and at 9 months were 71%.

Cite This Study

Raje et al. (2018) studied this question.

synapsesocial.com/papers/6a101de4d8c5cf602efdb212 https://doi.org/10.1200/jco.2018.36.15_suppl.8007

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows promising efficacy and safety of bb2121 CAR T-cell therapy in relapsed/refractory multiple myeloma, indicating a potential new treatment option.

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

Discussion

Member takes

Implication

Key Points

Cite This Study

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider